Received Aug 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (UNKNOWN)) | UNKNOWN MANUFACTURER | UNK | UNK | — |
| FLUX | INFLUENZA (SEASONAL) (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
experienced a facial palsy; This serious case was reported by a consumer via call center representative and described the occurrence of facial palsy in a male patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included COVID-19 vaccine for prophylaxis and Influenza vaccine for prophylaxis. On 17-JUL-2025, the patient received Shingrix, COVID-19 vaccine and Influenza vaccine. On 17-JUL-2025, less than a day after receiving Shingrix, COVID-19 vaccine and Influenza vaccine, the patient experienced facial palsy (Verbatim: experienced a facial palsy) (serious criteria hospitalization and GSK medically significant). The outcome of the facial palsy was unknown. It was unknown if the reporter considered the facial palsy to be related to Shingrix, COVID-19 vaccine and Influenza vaccine. The company considered the facial palsy to be unrelated to Shingrix. It was unknown if the company considered the facial palsy to be related to COVID-19 vaccine and Influenza vaccine. Additional Information: GSK Receipt Date: 31-JUL-2025 This case was reported by the wife of the patient. The reporter reported that her husband (patient) experienced a facial palsy after receiving Shingrix. The patient also received the Covid and Influenza vaccine the same day. Patient had to go the ER (emergency room) on 17th July 2025.; Sender's Comments: A case of Facial paralysis, less than a day after receiving Shingrix, in a male patient. Causal relation is indeterminate considering multiple vaccines given concomitantly.